The goal of this clinical trial is to compare a 755nm honeycomb picosecond laser versus a CO2 fractional laser for the treatment of atrophic acne Efficacy and safety of scarring.

The main questions it aims to answer are:

Effectiveness of 755nm Honeycomb Picosecond Laser and CO2 Fractional Laser in the Treatment of Atrophic Acne Scars

Effectiveness of scarring

Participants will:

the control group(receiving 10600nm CO₂ fractional laser[AFL]treatment)and the experimental group(receiving picosecond laser with honeycomb focusing lens array[P-DLA]treatment).Facial images were captured using the VISIA skin imaging system,and the red zone,UV spot,and brown spot scores were evaluated for all subjects before each treatment,and at 1 and 3 months post-treatment.

Inclusion Criteria:

1. Patients diagnosed with symmetrical atrophic acne scars on both sides of the face by a dermatologist; 2）Age ≥ 18 years old; 3) Voluntarily participate and sign an informed consent form.

Exclusion Criteria:

1. History of scar tissue in the past The person; 2) History of phototherapy such as laser and radiofrequency in the past 3 months; 3) History of photosensitivity or within the past 3 months Individuals who have taken photosensitive drugs; 4) Individuals allergic to lidocaine; 5) Individuals with coagulation dysfunction; 6) In the past 3 months History of oral corticosteroids and immunosuppressants; 7) Malignant tumor patients; 8) During pregnancy or lactation Women; 9) Individuals with local facial infections or injuries.